Steve Kelsey, M.D.

Stephen (Steve) Kelsey, M.D., MB ChB, FRCP, FRCPath is a highly-accomplished physician-scientist, oncologist and cancer drug developer and currently serves as president, research & development at Revolution Medicines. Prior to joining Revolution Medicines as president, research & development in 2017, Dr. Kelsey served as president of Onkaido Therapeutics, a Moderna Venture focused on oncology mRNA therapeutics. Prior to Onkaido, he served in senior positions at Medivation and Geron, where he led efforts to develop innovative cancer therapeutics. Prior to Geron, he served as vice president of hematology/oncology at Genentech, where he built the exploratory clinical development group and played a significant role in the development of key products Perjeta®, Kadcyla® and Erivedge®. He began his career in life sciences at Pharmacia/SUGEN where he led the initial clinical development and clinical proof-of-concept for sunitinib (Sutent®) in GIST tumors, resulting in its approval after the acquisition by Pfizer.

Before his transition to industry, Dr. Kelsey was a senior lecturer in hematology/oncology at St. Bartholomews and the Royal London School of Medicine and Dentistry. He was also director of the hematology/oncology Phase 1/2 clinical trials unit at Barts and the London School of Medicine and Dentistry and head of the Bone Marrow Transplant unit.

Dr. Kelsey holds bachelor of medicine and bachelor of surgery degrees (MB ChB), as well as a doctorate of medicine (M.D.) degree from the University of Birmingham, U.K. and is a fellow of the Royal College of Physicians (FRCP) of London and the Royal College of Pathologists (FRCPath), U.K.